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Abstract
Human mesenchymal stromal cells are regarded as the golden standard for cell-based therapies. They present multilineage
differentiation potential and trophic and immunosuppressive abilities, making them the best candidate for clinical
applications. Several molecules have been described to increase bone formation and were mainly discovered by candidate
approaches towards known signaling pathways controlling osteogenesis. However, their bone forming potential is still
limited, making the search for novel molecules a necessity. High-throughput screening (HTS) not only allows the screening
of a large number of diverse chemical compounds, but also allows the discovery of unexpected signaling pathways and
molecular mechanisms for a certain application, even without the prior knowledge of the full molecular pathway. Typically
HTS is performed in cell lines, however, in this manuscript we have performed a phenotypical screen on more clinically
relevant human mesenchymal stromal cells, as a proof of principle that HTS can be performed in those cells and can be used
to find small molecules that impact stem cell fate. From a library of pharmacologically active small molecules, we were able
to identify novel compounds with increased osteogenic activity. These compounds allowed achieving levels of bone-
specific alkaline phosphatase higher than any other combination previously known. By combining biochemical techniques,
we were able to demonstrate that a medium to high-throughput phenotypic assay can be performed in academic research
laboratories allowing the discovery of novel molecules able to enhance stem cell differentiation.
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Introduction
Osteoporosis and other bone-related disorders represent a major
public health threat. One out of every two women and one in four
men, aged 50 or older, is expected to develop an osteoporosis-
related fracture in their lifetime [1,2,3]. There is a huge demand for
products enhancing bone regeneration. Therefore, the last decade
was denominated the bone and joint decade by the World Health
Authority. Over the last years, hMSCs have become the golden
standard for cell therapy applications, mainly due to their multi-
lineage potential, but also due to their secretion of trophic and
immunomodulatory factors [4,5].
However,bonetissue engineeringusinghMSCsisbeinghindered
by the lack of markers predicative of bone formation and due to the
relatively poor performance of hMSCs, and there is therefore an
urgent need for new molecules able to induce their differentiation
potential with higher efficiency. In the past we and others have tried
different candidate approaches in order to enhance the perfor-
manceof hMSCs for bone tissueengineering applications,including
the effect of Wnt signaling on the proliferation and differentiation of
hMSCs [6], the effect of the inhibition of histone deacetylases on
mineralization [7], and the activation of the cAMP/PKA pathway
[8]. New technology is currently available in research laboratories,
allowing the discovery of unexpected signaling pathways and
molecular mechanisms for a certain application by screening
libraries of reagents such as small molecules, siRNA or peptides.
High-throughput screening (HTS) is a process that allows the
screen of thousands of chemicals in order to identify potential
interesting compounds for a specific application. HTS techniques
have been used for some years, but the technical settings and
especially the costs involved in its implementation have restricted
their application to large pharmaceutical companies. More
recently, this method has become more accessible and, therefore,
it is currently a technique that can be performed in an academic
setting. In pharmacology, HTS assays are usually developed based
on a certain target molecule in a cell line which is easy to culture.
However, for bone tissue engineering, the usage of this technology
for phenotypical screens in clinically relevant cells would be more
appropriate since it would allow the discovery of new compounds
and possible new target molecules for cell-based bone tissue
engineering. Using phenotypical assays, entire pathways of interest
can be discovered, providing the opportunity for multiple
intervention points, as opposed to a single direct molecular target
commonly used in biochemical approaches. Cell-based assays can
therefore be used to identify modulators of differentiation
pathways (for example osteogenesis) in the physiological environ-
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feedback control mechanisms present. The possibility to combine
compounds is almost unlimited and several libraries should be
explored. For bone tissue engineering, several approaches can be
undertaken including the screening of libraries of small com-
pounds (as described in this manuscript), the possibility to screen
libraries of biomaterials generated by combinatorial chemistry [9]
and libraries of surface topographies [10].
Although the design of the screens can vary, compound screens
are usually performed at single dosage and a single measurement
for each compound in the initial screen. This is frequently the only
option available to economically screen a large library of
compounds. Compounds identified are then re-tested and then
further evaluated at different dosages. After a compound is
validated by several techniques, it is usually considered as a lead
and then can be further tested as a potential drug candidate for
future clinical trials. Several aspects have to be taken into
consideration while designing a screen, and both false negatives
and false positives should be minimized by avoiding or correcting
systematic errors [11,12,13]. Frequently a cutoff is established
based on statistics to affirm positive compounds.
Alkaline phosphatase (ALP) is currently the most frequently
used marker for osteogenic differentiation and it has been
previously used as a readout in the search for novel osteogenic
suppressors in hMSCs [14], novel promoters and inhibitors of
osteogenic differentiation [15], and in the assessment of the
osteogenic capacity of several compounds [8,16,17].
Based on our experience in bone tissue engineering, we sought
to find novel osteogenic molecules by performing a phenotypical
screening of a library of pharmaceutically active compounds and,
therefore, we describe a simple, yet effective way of screening for
compounds in a common research laboratory without the need of
expensive robotic techniques.
Materials and Methods
Isolation, culture and characterization of hMSCs
Bone marrow aspirates were obtained from donors with written
informed consent and were approved by the medical ethical
committee of the University medical Centre Utrecht. Briefly,
aspirates (Table S1) were resuspended using 20 G needles, plated
at a density of 5610
5 cells/cm
2 and cultured in hMSC
proliferation medium (PM) containing a-minimal essential medi-
um (a-MEM, Life Technologies), 10% fetal bovine serum (FBS,
Cambrex), 0.2 mM ascorbic acid (Asap, Life Technologies), 2 mM
L-glutamine (Life Technologies), 100 U/ml penicillin (Life
Technologies), 10 mg/ml streptomycin (Life Technologies) and
1 ng/ml basic fibroblast growth factor (bFGF, Instruchemie). Cells
were grown at 37uC in a humid atmosphere with 5% CO2.
Medium was refreshed twice a week and cells were used for further
subculturing or cryopreservation when reaching 80–90% conflu-
ence. After expansion, cells were characterized for surface marker
expression (CD73, CD90, CD 105, CD11b, CD19, CD34, CD45
and HLA-DR) as previously described [18]. Furthermore, their
multilineage potential was confirmed by performing several
differentiation experiments [18]. hMSC basic medium/control
medium (BM) was composed of hMSC PM without bFGF. hMSC
osteogenic medium (OM) was composed of hMSC basic medium
supplemented with 10
28 M dexamethasone (dex, Sigma).
LOPAC library for the phenotypical screen
The Lopac library (Sigma-Aldrich) was purchased to screen for
osteogenic compounds. It is composed of 1280 pharmacologically
active compounds, with all multiple targets represented including
GPCRs, kinases and ion channels (see Figure 1B for a
representative diagram of the classes of action of the compounds
used on the screen). Many molecules are marketed drugs and have
pharmaceutically relevant structures, with predictable activity and
directed against a wide range of drug targets. The compounds are
highly purified, and the stock is pre-solubilized in DMSO. The
final compound concentration used in the screen was 4,5 mMi na
volume of 200 mL per well of osteogenic medium (OM),
containing 0.25% DMSO (v/v). In each test plate columns were
reserved for positive (OM+0.25% DMSO) and negative
(BM+0.25% DMSO) controls.
High-throughput assay (HTA)
To assess the osteogenic potential of the compounds present in
the HTA library, hMSCs were seeded at 2000 cells/cm
2 in BM
and allowed to attach overnight. The next day, medium was
changed to OM and test compounds and controls were added to
the plates. This initial screen was performed in hMSCs from two
different donors (D36 and D41) to cover possible donor variation
in the osteogenic response. After 4 days of incubation in OM,
relative cell number was determined by measuring acidic
phosphatase (ACP) activity [19]. First, cells were washed twice
with PBS (Life technologies) and lysed using 30 mL of 0.2% Triton
X-100 solution in 100 mM PBS pH 7.8, supplemented with a
protease inhibitor cocktail (Roche Applied Science). For the
measurement of cell numbers, 5 mL of the lysate was incubated
with 100 mL of 5 mM 4-nitrophenyl phosphate disodium salt,
dissolved in 0.1 M sodium acetate, 0.1% Triton-X, pH 5.5 for
1.5 hours at 37uC. After the incubation period, the reaction was
stopped by adding 10 mL of 0.5 N sodium hydroxide and allowed
to equilibrate for 10 min. The absorbance was then measured at
405 nm.
Alkaline phosphatase activity was measured using a biochemical
ALP assay. For this assay, part of the previously described lysate
was incubated in the dark at 25uC with CDP-Star substrate
(Roche) and allowed to react for 30 min. Luminescence was then
measured using a VICTOR
3 luminometer (Perkin Elmer) at 25uC.
The total ALP luminescence was normalized for cell number using
the ACP activity as readout.
Primary Screen validation and Statistic analysis
In order to measure the assay quality we used the most widely
accepted method, the Z9 factor [20]. This metric quantifies the
separation of a positive activity (positive control - OM) from the
background (negative control – BM) in the absence of test
compounds. To determine this factor the following formula was
used:
Z’~1{3|
sp{sn
jmp{mnj
where sp and sn are the standard deviations of the positive and
negative control, respectively, and mp and mn are their means. A
score of Z9$0.5 indicates and excellent assay, which is able to
discriminate positive hits from background noise.
The next step involved the selection of a meaningful cutoff on
the calculated statistics to declare positive compounds. Since it was
only possible to test 80 compounds per plate and since positive and
negative hits could easily influence the plate sample mean and
standard deviation, to establish the cutoff we calculated the
standard deviations from the trimmed mean of the tested
compounds. The top and bottom 10% of the tested compounds
were not taken into account for the calculation of the mean and
standard deviation and hits were selected if they were higher than
Osteogenic High-Throughput Assay on hMSCs
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independent screens.
Hit validation
The hit compounds obtained from the primary screen were
then re-evaluated at 10 different concentrations in order to obtain
the optimal concentration that induced the highest osteogenic
activity. All the compounds were serially diluted in half-
logarithmic steps, ranging from 3.16e
29 Mt o1 e
24 M. hMSCs
were seeded at 2000 cells/ cm
2 in triplicate in both basic and
osteogenic medium for 4 days. After this period, cells were lysed
and both cell number and ALP activity were calculated as
previously described. The optimal concentration was then selected
for further studies.
Next, we confirmed enhanced ALP expression as a secondary
screen by flow cytometry. Cells were seeded at 5000 cells/cm
2 in
basic medium (BM), allowed to attach for 10–15 h and then
cultured for 4 days in both BM and OM. Each experiment
consisted of a negative control (cells grown in BM), a positive
control (cells grown in OM), and one or more experimental
conditions. Experiments were performed in triplicate and at least
10000 cells were measured. After 4 days of treatment, cells were
trypsinized and incubated for 30 min. in phosphate-buffered saline
solution (PBS) containing 5% bovine serum albumin (BSA), after
which cells were further incubated in PBS-1% BSA containing
primary antibody (anti-ALP B4-78; Developmental Studies
Hybridoma Bank, University of Iowa, Iowa City, IA) for 1 hr.
Cells were then washed and incubated with secondary antibody
(goat anti-mouse IgG conjugated with phycoerythrin [PE]) for
30 min. After incubation, cells were washed three times and
resuspended in PBS-1% BSA. Viaprobe (BD Biosciences) was
added for live/dead staining and allowed to incubate for 10 min.
Cells were then analyzed using a BD FACScan (BD Biosciences)
and ALP levels were determined on live cells only.
Results
Assay Development
When developing an hMSC-based assay there are several
critical steps, being reproducibility and assay validation the most
important ones. A high-throughput assay was established as shown
in Figure 1. On day 0, hMSCs were dissociated using trypsin and a
single cell suspension was obtained. hMSCs were then seeded in
96-well plates at 1000 cells/well in basic medium (BM) for one
day, which allowed them to attach and recover better from the
trypsinisation process. Medium was then changed to osteogenic
medium (OM) and a library of 1280 active compounds were tested
for 4 days. This period of time was considered optimal since it did
not require re-addition of compounds and change of medium. For
the selection of positive compounds, we used a luminescence-based
ALP activity assay, and ACP activity to correct for cell number.
This combination of assays works well and was compared with
others such as CellQuant and para-nitrophenyl phosphate (pNPP)
based-ALP measurement, yielding similar results, but reducing
significantly the timeframe and workload (data not shown). In
order to validate the assay, the Z score was calculated for each
plate individually and for a control plate. The values ranged from
0.6 to 0.7, meaning that the HTA is able to discriminate possible
hits from statistical noise on a given plate. With this methodology
we achieved a reliable and relatively fast method to screen libraries
of compounds with osteogenic potential.
Screening of the LOPAC library
In order to investigate new molecules with osteogenic potential,
high-throughput assays of a library of 1280 pharmacologically
active compounds were performed in hMSCs from 2 donors (D36
and D41). The compounds were screened at a single dosage of
4.5 mM in a volume of 200 mL per well of osteogenic medium
(OM), containing 0.25% DMSO (v/v). ALP levels were normal-
Figure 1. High-throughput Assay. A) Schematic representation of HTA: hMSCs were grown on proliferation medium, dissociated using trypsin
and plated into 96 well plates at a density of 2000 cells per well in osteogenic medium. Cells were allowed to attach for 24 h, after which medium was
refreshed and compounds and controls were added to each plate. After 4 days, both ALP activity and proliferation was measured in a fluorescence
plate reader. The compounds activity was evaluated in relation to the controls used. Positive compounds were then further confirmed by FACS and
taken for further analysis. B) Representative diagram of the classes of action of the compounds used for the screen (Lopac library, Sigma-Aldrich).
doi:10.1371/journal.pone.0026678.g001
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exclusion criterion, since for bone tissue engineering, proliferation
is crucial in order to achieve proper differentiation. Only the
compounds that were able to induce ALP above 3 SD-away from
the trimmed mean of its plate and did not present a significant
reduction of proliferation were taken into account. These hits were
then compiled and only the ones appearing in more than one
screen (on both donors tested) were taken for further studies. In the
initial screens, 29 and 32 hits were obtained, from which 14 were
present in both screens.
With ACP as readout, we have assessed whether any
compounds exerted a mitogenic effect, and although some
compounds did enhance significantly the proliferation of certain
donor cells, there were no compounds that were able to
significantly enhance proliferation in both donors tested, possible
due to the fact that the mitogenic effect of the compounds was
donor-specific.
Selection of the optimal concentration
After the compounds were selected from the primary screen, a
subsequent dose-response curve was established in both basic and
osteogenic medium. From the 14 compounds obtained in the
initial screen, 2 were not available for retesting. An example of this
assay for one compound (H-8) can be seen in Figure 2A. When H-
8 is added to basic medium, at a concentration of 1 mM, an
induction of ALP activity(<26) can be seen (Figure 2A1), lower
concentrations do not produce any effect and higher ones present
a decrease in total ALP activity. This decrease in ALP activity can
be explained by a profound decrease in cell proliferation at
concentrations higher than 3.16 mM (Figure 2A2). The same
phenomenon occurs in osteogenic medium where dexamethasone
is present, however a synergistic effect can already be seen for
concentrations as low as 1 mM. Although adding 3.16 mM of H-8
to the medium induces a higher ALP activity per cell than 1 mM
(Figure 2A3), the latter was chosen for further studies, since the
former presents significant cytotoxicity (Figure 2A2). The same
concentration range was used for all the different compounds and
the optimal concentration obtained for each compound was then
used for further studies. From the 12 compounds tested, we
confirmed 5 (Figure S1). The induction ratios (ALP activity,
proliferation and ALP per cell) of the compounds validated at the
optimal concentration were compared to the control situation
(basic medium) and are represented in Figure 2B. The compounds
that induced higher ALP activity were H8 and Pinacidil when
used in combination with dexamethasone.
Hits Validation by flow cytometry
After the compounds were assessed for the optimal dosage to
induce the highest ALP activity (marker for bone formation)
without interfering significantly with proliferation, they were
Figure 2. Hit validation. After being selected from the primary screen, the identified compounds (hits) were subjected to half-logarithmic dilutions
in order to assess the optimal concentration of each compound that would induce the highest alkaline phosphatase (ALP) activity. The graphs
represent: A1) ALP activity; A2) ACP activity A3) ALP activity/cell, in both basic and osteogenic medium when supplemented with different
concentrations of the compound H-8 (as example, since the same was performed for all the hits obtained); B) The table represents the ALP-induction
ratio when compared to the control situation (basic medium).
doi:10.1371/journal.pone.0026678.g002
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D41 and D42) by flow cytometry, using an antibody against bone/
liver/kidney-specific ALP. The percentage of cells expressing the
ALP marker was evaluated and all the conditions were compared
to either basic or osteogenic medium. Figure 3 represents the data
from D41 (one of the donors used in the initial screen (Figure 3A),
and since some donor variation was present, we also include a
table that summarizes the number of donors where each
compound was effective (Figure 3B). In the cells from D41 (A),
we can observe that in control medium, the maximum effect of a
compound in basic medium (BM) was an increase from
29.37%61.44 of ALP positive cells (BM) to 38.12%61.20 (when
H-8 was added to BM). However, it is clear that the best effect
obtained by any compound is achieved when osteogenic medium
(OM) is used. While the compound with less effect in this donor
(Pinacidil) is able to synergistically increase the % ALP positive
cells from 44.19%64.44 (OM) to 50.62%61.63, others (H-8 and
Propentofylline) can significantly increase it up to 69.76%60.68
and 69.46%61.30, respectively, representing a 57% increase over
dexamethasone (the reference osteogenic molecule). However, not
all the compounds exhibited a consistent effect on the four donors
tested (Figure 3B). Only one compound (H-8) was able to induce
ALP in both BM and OM in the four donors tested, while 2
compounds (H-8 and GW 5074) were able to induce it in OM
medium. The compound with the mildest effect was Propentofyl-
line, since it only increased ALP in one donor (D41), although in
that particular donor, was able to induce it significantly (from
44.1964.44% of positive cells to 69.46%61.30, representing
a<57% increase over dex. alone) (Figure 4A). In this donor,
except for Pinacidil, all the other compounds that were used in
OM, were able to significantly enhance ALP levels when
compared to Dexamethasone alone (OM), showing that they were
able to synergistically enhance ALP expression. When used alone
(BM) only H-8 and Propentofiline were able to significantly induce
ALP (Figure 3A).
An overview of the average induction level (for 3 extra donors
D26, D38 and D42) of each compound tested compared to the
control can be seen in Figure 4. For each condition, data
represents the average of the percentage of ALP positive cells for
the three donors tested and was divided by the average of the
controls to achieve the induction ratio. As can be seen from
Figure 4A, the compound that induces most ALP, in basic
medium, is dexamethasone (positive control) with an average of
2.42 times more ALP-positive cells than the control. However the
induction ratio varied largely between donors (1.50 to 3.69) as seen
by the standard deviation (Figure 4A) and the data present in
Figure 4C. From the compounds obtained in the screen, only H-8
and SQ 22,536 induced significantly more ALP positive cells than
the control. However, when the compounds were added to OM
(Figure 4B), all compounds induce an average ALP expression
higher than the control (OM), showing that they synergistically act
with dexamethasone to enhance ALP. The donor variation
observed is depicted in Figure 4C (BM) and 4D (OM).
Comparison of the validated hits with the reference
osteogenic molecules
After performing the validation of the hits, we tested their
activity in the context of other known compounds with known
osteogenic activity (Figure 5). N
6,2 9-O-dibutyryladenosine 39,59-
cyclic monophosphate sodium salt (cAMP) was used as a reference
osteogenic molecule since we have previously shown that PKA
pathway activation (by cAMP) in hMSCs in vitro results in robust
bone formation in vivo [8]. The highest percentage of ALP positive
cells was obtained when reference molecules vitamin D3 and
dexamethasone (41.67%60.22) were combined (OM+VitD3)
(Figure 5A). This combination yielded a significantly higher
percentage of ALP-positive cells than the combination of cAMP
and dexamethasone (p,0.01), or dexamethasone alone (p,0.001).
Supplementing this combination (OM+VitD3) with H-8 increased
the percentage of ALP positive cells even further to 55.16%60.77,
representing an approx. 13% increase (Figure 5C). However, the
addition of H-8 alone to OM already induced 50.13%60.46 of
cell to express ALP (Figure 5C). Even in the basic medium, the
addition of H-8 was able to increase the percentage of ALP-
positive cells by 50%, from 11.15%60.85 (BM) to 22.56%61.06
(BM+H-8) (Figure 5B). The addition of H-8 to known osteogenic
Figure 3. Confirmation of the Hits by flow cytometry on ALP. A) Evaluation of the osteogenic potential of several treatment conditions by
flow cytometry on hMSCS after 4 days treatment. Data is expressed as percentage of ALP positive cells. At least 10,000 cells were measured for each
condition and experiments were performed in triplicate. Error bars represent standard deviation. Statistical analysis was performed using (one-way
ANOVA and Tukey post-test with a significance level of 0.05. Asterisks represent * P,0.05, ** P,0.01 and *** P,0.001. BM (basic medium); OM
(Osteogenic Medium); DEX (Dexamethasone). B) Number of donors in which the respective compound had a positive effect on ALP induction both in
basic or osteogenic medium.
doi:10.1371/journal.pone.0026678.g003
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synergistic way (Figure 5C), except with cAMP where the changes
induced by the addition of H-8 were not significant. Since lithium
is known to inhibit the osteogenesis via Wnt signaling in hMSCs,
we also tested the effect of lithium to H-8-induced ALP expression.
The addition of lithium did not have any effect on H-8-induced
ALP (Figure 5B), suggesting that the ALP induction by H-8 was
not inhibited by the Wnt signaling pathway.
General Overview
A general overview of the results is described in Figure 6. From
the total 1280 compounds, 14 were selected for subsequent dose-
response assays, in order to find the optimal dose to induce ALP.
From the 14 selected compounds, 2 were not possible to be tested,
and from the 12 that were assayed, 5 exhibited dose-depend effects
on ALP induction. The list of the 5 compounds can be found in
Figure S1. The hits were then tested further by flow cytometry on
three other donors, which resulted in 4 compounds with consistent
ALP induction above the controls (Dexamethasone) and one
(Propentofylline) that presented a non-significant increase in ALP
expression in most donors. Based on this, H-8 is the most
promising compound for future in vivo studies.
Discussion
Design of the High-throughput assay
When designing an HTA/ HTS the first consideration should
be the goal of the screen and then the type of assays that would
allow achieving that goal with the highest efficiency. Since our
primary goal was to search for novel molecules with high
osteogenic activity, the type of cells and readout marker to be
used was our first consideration. Concerning cells, there were two
immediate possible choices available, each one with their
advantages and drawbacks. We had to choose whether we would
use a highly homogeneous and abundant cell line with osteogenic
potential (such as C2C12 or MC3T3) or use human primary cells
derived from bone marrow biopsies. While the first ones provide a
more homogeneous cell source which will possibly result in an
increased reproducibility between assays, they are isolated from
mouse and are immortalized cell lines. Therefore, the results
obtained could not directly been extrapolated to the human
situation, without previously take in consideration, the species
difference and even the differentiation state of the cells. An
example is the usage of cAMP as an osteogenic inducer, where we
have shown that the same compound results in an opposite effect
when used in human cells as opposed to rodent models [21]. This
study stresses the need that research experiments should be
performed in more clinically relevant models.
Human mesenchymal stromal cells do not present the problem
of species variation, however they are more heterogeneous, less
abundant and present donor variation [22]. Nevertheless, when
care is taken in the isolation of the cells and in the design of the
experiment, most of these factors can be overcome. We therefore
fell that the use of human primary cells is more clinically relevant
and although more cumbersome since cells from different donors
have to be used, it also contributes for the strengthening and
validation of the results for possible future clinical applications.
Furthermore, since HMSCs are multipotent, they could be a
Figure 4. Confirmation of the hits by flow cytometry in 3 extra donors. A,B) Evaluation of the osteogenic potential of several treatment
conditions on hMSCS after 4 days. Data is expressed as ALP induction ratio. Data reflects the average of induction of the percentage of ALP-positive
cells of each condition divided by the average of induction of the percentage of ALP-positive cells of the respective control (A – basic medium and B
– osteogenic medium). Each experimental condition was performed in triplicate and data reflects the results of 3 independent donors). C,D) Table
depicting the donor variation on the induction of the percentage of ALP positive cells after each experimental condition when compared to the
respective control.
doi:10.1371/journal.pone.0026678.g004
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compounds validated (H-8) and all the possible combinations with the reference osteogenic molecules. Graphs represent the % ALP-positive cells of:
the controls (A), the different combinations possible in BM (B) and the different combinations in OM (C). The osteogenic potential of each treatment
was assessed by FACS after 4 days, in at least 10000 cells, in triplicate. Error bars represent standard deviation. Statistical analysis was performed using
one-way ANOVA and Tukey post-test with a significance level of 0.05. Asterisks represent * P,0.05, ** P,0.01 and *** P,0.001. OM – basic medium
supplemented with dexamethasone; cAMP – di-buteryl cyclic AMP, DEX – dexamethasone, NS – non significant.
doi:10.1371/journal.pone.0026678.g005
Figure 6. Results from the Lopac library screen. Diagram showing the results obtained from the 1280 compounds library screen. The evaluation
process was composed of 4 main steps. 1. Selection of the compounds from the primary screen compared to the controls. 2. Dose-curve evaluation
of the optimal concentration to be used (fluorescence-based read out). 3. Confirmation by FACS of the hits in cells from 3 other donors. 4.
Confirmation of the osteogenic potential and comparison to the reference osteogenic compounds known so far. Out of 1280 compounds, 14 were
identified in the primary screen, which were then subjected to dose-response analysis resulting in 5 hits. From these 5 hits, 4 were confirmed by FACS
to have enhanced osteogenic potential in most donors. These 5 compounds (leads) were then further evaluated in 3 other donors and compared to
reference osteogenic compounds which have resulted in novel osteogenic combinations with increased osteogenic potential that were never tested
before. * Compounds not tested were discontinued from the manufacturer or had problems with solubility and therefore were not in conformation
with the manufacturers specifications. ** Candidate molecule for in vivo studies, proven to induce osteogenesis in all donors tested and had a
synergistic effect with reference osteogenic molecules.
doi:10.1371/journal.pone.0026678.g006
Osteogenic High-Throughput Assay on hMSCs
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26678useful tool to unveil compounds that influence cell fate decisions.
In this manuscript, we show that some compounds that induce
osteogenesis are donor-specific, while others are able to robustly
induce in all donors tested, making them better suited for in vivo
studies.
For a fast and efficient high-throughput screening several factors
are needed, one of them being the choice of the assays used as
readout. They should be fast, economic, efficient, reproducible
and, in the case of HTS, they should be simple enough to allow
automation. The first step was the choice of assay to be used to
determine cell numbers. Several methods exist, either by the direct
or indirect determination of cell number, including cell counting
using a microscope or a particle counter [23], determination of
cellular protein or DNA [24,25,26], measurement of 3H-
thymidine incorporation [25], measurement of the uptake and
conversion of tetrazolium dyes such XTT, MTS, and MTT
[27,28,29,30], or by measuring cellular enzymes such as lactic
dehydrogenase [31]. However, most of them fail to obey to the
desired characteristics mentioned above especially because most of
them are time-consuming, therefore offering limited use in large-
scale screening experiments. Another major limitation is that most
of these methods are not sensitive enough to determine very low
numbers of cells (less than 1000) and simple enough to be
automated. When analyzing the effect of drugs on cell prolifer-
ation, one has to realize that these compounds can often be
cytotoxic and therefore, it may be that in some wells the amount of
cells is limited, therefore, high-sensitivity is a prerequisite.
Although, the assays based on cellular uptake and reduction of
tetrazolium dyes are considered by some authors as the quickest,
simplest, and most sensitive of the methods mentioned above, they
offer several limitations [27]. These limitations include the fact
that dye-based assays frequently suffer from high background
signals, lack of reproducibility and limited linear response, in
addition to the fact that some human cells metabolize tetrazolium
dyes very inefficiently, not to mention that in some cases such dyes
are even toxic to cells. In our screen we choose to use a well-
established method to detect the activity of acidic phosphatase,
due to the several advantages that this method offers on
comparison to others. It is a simple method, it allows automation,
can be performed in frozen lysates, it is inexpensive, reproducible
and sensitive enough to detect low cell numbers. Acidic
phosphatase activity assays can be performed since the endoge-
nous levels of this enzyme is relatively constant in many cell types
under different culture conditions and these methods have been
proven to be the most sensitive and reproducible for counting
different cell sources [19].
For the ALP activity quantification there was the possibility of
quantifying it by using pNPP as substrate (colorimetric) or a
luminescence method based on the conversion of the substrate
CDP-Star (Roche). CDP-Star is a chemiluminescent substrate for
alkaline phosphatase that enables an extremely sensitive and fast
detection of biomolecules. It generates a luminescence signal
which is approximately 10 times stronger than comparable
chemiluminescent substrates and the signal is stable for long time.
This method is fast, sensitive, presents very high signal to noise
ratio and it is easily automated. After careful optimization and
validation we decided to use this method for the detection of ALP
activity.
Since the compounds were dissolved in DMSO the initial
concern was to assess the potential toxicity of the dosage to be
used. By reducing the amount of DMSO used in relation to the
total volume of medium we achieved a very low final DMSO
concentration (0.25%) reducing significantly DMSO cytotoxicity
(data not shown). Controls were used in each plate to assess for
DMSO effects and also to provide a reference for the compounds
being tested. We also opted to change medium in the plates only
before the addition of the compounds present in the library. Thus,
we used the compounds of the library only once, reducing the costs
in both compounds and materials, in addition to the labour
needed to replace the old medium and add new compounds. It
also decreased the potential effect of adding DMSO for a second
time, and since we previously knew that ALP was expressed at
higher levels already after 4 days, we opted for the convenience of
the screen, to use this time frame for the assay.
Hit Rate on HTS screens and advantages of phenotypical
screens
One of the biggest problems in high-throughput screening
experiments is the amount of false positive hits (inactive
compounds misidentified as active by the primary screen). The
concept of hit-rate designates the ratio of the number of actives to
the number of compounds screened. Hit rates vary largely
amongst screens and depend on several factors for instance
whether the screen uses unknown synthetic compounds or ‘‘known
bioactives’’. Despite known bioactive libraries are typically much
smaller than commercial libraries of unknown synthetic com-
pounds, they typically have a significantly higher hit rates than the
libraries of synthetic compounds [32]. In our screen of bioactive
compounds, 14 hits from a total of 1280 compounds tested were
obtained, which corresponded to 1,09% of all compounds tested.
Then on the counter screen (the dose-curve experiment) only 5 of
the initial hits were confirmed and therefore, effectively, only
0,39% of the total screened compounds went for further
validation. These hit rates are in line with other high-throughput
screens (HTS), and as an example, in the siRNA library screen for
osteogenic suppressors the hit rate was around 1,06% [14], while
in another HTS based on ALP as readout the hit rate for
promoters of osteogenesis was around 3,46% [15]. The percentage
varies largely among bioactive screens, and in some cases the hit
rates can be as high as 53,8%, as was the case of a screen for
activators of deacetylase activity of purified Sirt1, where 1,151
initial hits were obtained out of 2,139 molecules screened
(ChemBank). Without prior consideration of the true number of
active compounds present in a library for the application in study,
one cannot foresee the number of hits expected to be obtained in
the first screen.
Validated hits and their mechanism of action
The compounds selected as hits do not induce osteogenesis via
the same signaling pathways, however, most of them are somehow
involved in either the Raf-MEK-ERK or the cAMP signaling
pathway. This discovery is in line with our previous findings that
cAMP can mediate osteogenesis [8].
The most promising compound from the screen that was proven
to enhance ALP formation in all the donors tested is H-8, which
has been described as a potent, cell-permeable, reversible and
ATP-competitive inhibitor of cyclic-nucleotide protein kinases. It
is known to inhibit protein kinase A(PKA), myosin light chain
kinase (MLCK), protein kinase C (PKC) and protein kinase G
(PKG) [33]. We previously reported, and show in Figure 5, that
cAMP induces ALP expression, which is mediated via the
activation of protein Kinase A (PKA). Yet, H-8 is still able to
enhance significantly the ALP levels, apparently independent of
PKA activity. The mechanism by which this occurs is still
unknown. As mentioned, the mechanism of action of H-8 is
broader than PKA alone. Similarly, a number of studies have
identified that the action of 2 other PKA inhibitors (H89 and KT
5720) are independent of their effects on PKA. Low specificity of
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on other protein kinases and signaling molecules and also on basic
cellular functions, such as transcription [34].
Interestingly, the other compound that was also able to increase
the dex-induced ALP in all the tested donors was GW 5074, which
is a Raf 1 kinase inhibitor, immediately downstream of Ras in the
MAPK signaling pathway [35]. Amongst other effects, it stimulates
Raf-MEK-ERK pathway and enhances the effects of most HDAC
inhibitors [36].
The third compound more effective in OM was Pinacidil, which
is a KATP channel opener, known to hyperpolarize various cell
types. Both Pinacidil and other KATP channel openers like
Diazoxide, are known to elevate bone marker expression, namely
BSP and ALP, and it was shown that endogenous hyperpolariza-
tion is a functional determinant of hMSC differentiation and a
possible control point for modulating stem cell function [37,38].
The other compounds selected as hits are both involved in the
cAMP signaling however their effect seems to be somehow
antagonist, which might lead to the speculation that their effects
could be broader than the cAMP pathway itself. One of these
compounds is SQ 22,536. It is a cell-permeable adenylate cyclase
(AC) inhibitor [39] and since AC is the main responsible for the
transformation of ATP to cyclic AMP (cAMP), the addition of SQ
22,536 should result in a decrease in cAMP levels, which is in
contradiction with our previously published data [8] but in line
with the results obtain with the compound H-8 and with the report
on the siRNA library screen for osteogenic suppressors [14].
However as a note, this compound was only effective in half of the
donors tested and when all the donors are taken into account the
addition of SQ 22,536 presented an average higher ALP than
OM, but this increase was not significantly different. It could be
that the increase on ALP observed could be via other pathway
than the cAMP one, since it was recently proven that many
compounds involved in cAMP pathway have a broader action
than what was previously known.
The last compound is Propentofylline. It is a cAMP phospho-
diesterase inhibitor, an adenosine transport inhibitor and a non-
selective adenosine receptor antagonist. It has been proven to
decrease free radical formation and lipid peroxidation [40], to
reinforce the cAMP signaling and enhance the cAMP levels in
plasma of mice [41]. Its predominant mechanism of action
appears to be causally related to an increase of tissue cAMP/
cGMP mainly by a) an indirect reinforcement of A2 receptor
mediated cAMP formation (via adenosine transport blockade) and
b) hindrance of intracellular cAMP breakdown (via inhibition of
cAMP- and cGMP-PDEs). As a note, this compound was only
active in one of the donors used to validate the screen results, but
in this particular donor, the increase in ALP expression was
approx. 57% more than dexamethasone alone, which was highly
significant. However this effect appeared to be donor specific.
Despite some of these compounds interact in pathways that are
known to control osteogenesis, the full mechanism of action of
some is still unknown. In phenotypical screens, however, the effect
of a compound on the phenotype of choice, in this case osteogenic
differentiation, is the relevant read-out. Even without detailed
molecular knowledge on the mechanism of action of compounds,
the positive effect of them can be exploited. Nevertheless, further
work needs to be performed to deepen the knowledge of the
signaling pathways investigated and should be regarded as an
extra tool to reveal potential drug targets for future manipulation.
Conclusions
In this manuscript we show that by performing an HTA we
were able to obtain compounds that are able to enhance ALP
expression (the best known indicator of osteogenic differentiation)
even when compared to the reference osteogenic molecules
(Dexamethasone, Vitamin D3, cAMP). The results obtained by
this HTA show that many more compounds have the potential to
induce ALP, and prove that this methodology can be very effective
in discovering novel compounds with osteogenic potential or novel
functions to currently known compounds. Furthermore, this type
of HTA can be easily extrapolated to other differentiation
experiments, once the methodology is changed.
In this screen only a relatively small library of compounds was
tested (1280 compounds) and therefore many other libraries can
reveal compounds that are still not known to induce osteogenesis.
What would be equally interesting and highly valuable for the
research in bone formation, would be the discovery of bone
formation markers that are able to predict bone formation more
efficiently, making the HTS with those markers even a more
valuable tool towards improved bone formation and hopefully
making the transition from bench to bedside quicker.
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